Philadelphia-based ERT, a global provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials. The new offering, which comprises the EXPERT3 workflow platform and MyStudyPortal3 reporting engine, can simultaneously process health outcomes data across cardiac safety, Clinical Outcome Assessment (COA)/ePRO and respiratory studies. The platform offers users a simple way to process multiple types of data accurately, leading to fewer errors in studies.
Built on ERT’s EXPERT technology that underpins all of ERT’s data acquisition, analysis and reporting, the new integrated platform can support more studies concurrently and is able to process a combination of data across multiple therapy areas. It supports a full suite of COA/ePRO, cardiac safety and respiratory devices, as well as a range of clinical endpoint devices such as glucometers and activity monitors.
“As the industry continues to search for ways to produce the most accurate data possible, this enhanced solution will enable clinical researchers to make better timely decisions relating to the progression of their studies, reducing the economic and time burden of unsuccessful studies and compounds and, ultimately, helping pharmaceutical companies to improve the development of new drugs,” said Jeffrey Litwin, CEO of ERT.